This announcement is a separate document:
クリングルファーマ：脊髄損傷急性期第III相試験のトップラインデータ及び2024年９月期第１四半期決算についての説明資料
Kringle Pharma: Explanatory materials on the top line data for the acute phase III trial of spinal cord injury and financial results for the 1st quarter of the fiscal year ending 2024/9
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.